Mr. William Wells, shareholder, reports

CONCERNED SHAREHOLDERS OF BIONICHE ANNOUNCE ADDITIONAL NOMINEE TO BIONICHE BOARD AND REITERATE THEIR DEMAND THAT BIONICHE IMMEDIATELY CALL A SPECIAL SHAREHOLDERS' MEETING

The group of concerned shareholders of Bioniche Life Sciences Inc. led by William (Bill) M. Wells, former chief executive officer of Biovail Corp.; and Greg Gubitz, former general counsel and senior vice-president of corporate development at Biovail, will also nominate Anthony Macci for election to the Bioniche board of directors.

Mr. Macci has extensive experience in manufacturing and supply chain management relating to the pharmaceutical, biotechnology and life science industry (including in the animal health field), and is a strong addition to the six highly qualified nominees previously identified by the concerned shareholders in their press release of May 14, 2013.

The concerned shareholders also reiterated their demand that the Bioniche board of directors cease employing stalling and obstructionist tactics, and set a date for a special meeting of Bioniche shareholders to consider the replacement of the Bioniche board with the nominees proposed by the concerned shareholders. Mr. Wells has submitted two valid requisitions to the Bioniche board of directors requiring the Bioniche board to promptly call the special shareholders meeting.

The concerned shareholders look forward to sharing their plans and strategies for Bioniche as soon as the Bioniche board properly calls the special shareholders meeting as required by statute and in accordance with the board's fiduciary duties to the company.

Time is of the essence. The company is hemorrhaging and rapidly running out of resources. Further delay is extremely prejudicial to shareholder value, and places the company in a precarious financial and business position. The board's artificial attempt to circumvent Mr. Wells's requisitions by calling a shareholders meeting for Nov. 5, 2013, is nothing more than a sham that seeks to circumvent shareholder rights. The concerned shareholders and the company's other shareholders cannot and will not wait until Nov. 5. The current board has had years to turn the situation around and has completely failed to do so. It is time to let the shareholders have their say.

It is time for new direction and new leadership. The board nominees proposed by Mr. Wells provide an excellent combination of life sciences expertise, public company corporate governance experience and, most of all, demonstrated success. They have proven they can deliver significant value to shareholders in their past endeavours, as most of these nominees worked together turning around Biovail to deliver superior results as a highly effective team.

This press release is not and does not constitute a solicitation of proxies.

Mr. Macci, New Jersey, United States

Mr. Macci has extensive experience in manufacturing and supply chain management relating to the pharmaceutical, biotechnology and life science industry. He is currently the senior vice-president, global operations, at Capsugel, a global leader in innovative dosage forms and solutions for the health care industry. From 2011 to 2012, he held the position of vice-president, quality and strategic supplier management, at Caris Life Sciences, a leader in diagnostic, prognostic and theranostic medicine. From 2010 to 2012, Mr. Macci also acted as a consultant to companies in the pharmaceutical, biotechnology and life science industry providing strategic, executive and operational consulting in manufacturing, supply chain, quality management, strategic procurement and business development. From 2008 to 2010, Mr. Macci was the senior vice-president, global operations, for Phibro Animal Health Corp., a global manufacturer of pharmaceuticals, vaccines and nutritional products. From 1987 to 2008, Mr. Macci was employed by Schering-Plough Corp., a United States-based pharmaceutical company, which has since merged with Merck & Co. During this time he held a variety of positions in support of the human pharmaceutical and animal health businesses, including vice-president, divestiture businesses, and head of the Americas and the Pacific regions, and vice-president, global supply chain.

Mr. Macci received a bachelor of science in pharmacy from Duquesne University in 1982 and a master in business administration from Iona College in 1996. He is a registered pharmacist in New York and Pennsylvania.

Bioniche securities held:  Nil